Scott M. Rocklage Ph.D. has been a 5 AM Ventures sitting managing partner since 2004, he joined 5 AM ventures in 2003 as a mere venture partner. Dr. Rocklage has gained his unquestionable health matters experience in over two decades.
His strategic leadership responsibilities led to approval of Omniscan, Cubicin and Teslascan United state New Drug Applications by the Food and Drug Administration. These drug applications entered six drug candidates into clinical experiments.
Previously, DR. Rocklage served as Cubist Pharmaceuticals chairman and CEO. He also served as Nycomed salutary president and CEO.
Scott has maintained his presidential, CEO and chairman seats at salutary and catalytic. Dr. Rocklage currently works at Achaogen, Semprus BioSciences Corp, and Relypsa as the board of chairman. At Whitehead Institute, he is one of the Board of associates.
Dr. Scott Rocklage also serves on the boards of Pulmatrix, WaveRx, and Variation. Earlier, DR. Scott Rocklage worked at Ilypsa and Miikana as the executive chairman but the firms were later acquired by Amgen and EntreMed respectively.
He has headed Novira Therapeutics, Inc as the chairman since August 2012. He is currently Kinestral board member. He also serves Rennovia Inc Board Chairman.
The Waltham, MA office Dr. Rocklage went to the University of California, Berkeley where he graduated with bachelors of Science in chemistry. He advanced for a Ph.D. in chemistry at Massachusetts Institute of Technology.
Scott Rocklage conducted research in the 2005 Nobel Prize winner Richard R Schrock laboratory. Dr. Rocklage has invented and co invented more than thirty United State patents and has more than one hundred peer-reviewed publications
Scott Rocklage is an entrepreneur who is very well organized with time management, prioritization, and calendaring regards.
He has gained a considerable healthcare management experience, scientific background and strategic leadership track record He works with scientist, physicians or business executive’s entrepreneurs to help them shape their ingenious ideas into currently unrealized medicines that can treat unmet health needs.
Read more: Scott Racklage | Crunchbase